Delhi-based pharmaceutical company Akums Drugs and Pharmaceuticals Limited on Thursday, November 13, reported a 37.6% year-on-year dip in net profit at ₹ 41 crore for the second quarter ended September 30, 2025. Net profit in Q2FY25 stood at ₹65 crore.

Revenue went down marginally by 1.5% to ₹ 1,017.5 crore from ₹ 1,033 crore in the year-ago period.

Earnings before interest, tax, depreciation and amortisation (EBITDA) decreased by 22.4% from last year at ₹94 crore, while the EBITDA margin shrunk 250 basis points to 9.2% from 11.7% a year earlier.

The company's board approved an investment of roughly ₹ 200 crore in its Zambia-based subsidiary, Akums Healthcare (Zambia) Private Limited,

"The purpose of this investment is to set up a manufacturing facility and to expand its b

See Full Page